The Asia Pacific Gastrointestinal Therapeutics Market should witness market growth of 4.7% CAGR during the forecast period (2022-2028).
Gastrointestinal disorders are among the most common complaints made to a primary care physician globally and are also connected with the substantial healthcare and economic burden. However, despite the prominent healthcare and financial burden of GI disorders, many digestive diseases are still under-researched.
In addition, the treatment options are not beneficial enough, leaving the patients dissatisfied with their present treatment. Thus, from a volume/value point of view, the significant area of unmet requirement and room for further development, combined with the large share of the pharmaceutical sector, make the GI therapeutics market an attractive target for therapeutic effect, where the development of new, affordable, and innovative, effective treatments could provide greater patients satisfaction, higher profit returns, and decreased economic burden.
In patients with GORD, one of the largest and fastest growing GI segments, the liquid content of the stomach regurgitates back up into the esophagus, causing ulcerations of the esophagus. The predominant symptom of which is the unpleasant sensation of heartburn, prominently at night. Acid suppressants used in the treatment of GORD include proton pump inhibitors, histamine H2 receptor antagonists, and antacids; however, proton pump inhibitors (PPI) have emerged as the most effective option for treatment.
Disease and illnesses of the gastrointestinal system have increased significantly in the last decade because of the considerable lifestyle changes. People with gastrointestinal illness have a high prevalence of depression, impaired central nervous system functioning, anxiety, and stress. The overall majority of self-reported gastrointestinal problems was 18%, with prominent variations among regions, and it increased with the rising age. Adults from the age group 45-54 and 55-64 years were prominently more prone to have gastrointestinal problems when compared to people below 44 years of age.
The China market dominated the Asia Pacific Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3, 846.3 million by 2028. The Japan market is experiencing a CAGR of 4.1% during (2022-2028). Additionally, The India market would display a CAGR of 5.3% during (2022-2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Gastrointestinal disorders are among the most common complaints made to a primary care physician globally and are also connected with the substantial healthcare and economic burden. However, despite the prominent healthcare and financial burden of GI disorders, many digestive diseases are still under-researched.
In addition, the treatment options are not beneficial enough, leaving the patients dissatisfied with their present treatment. Thus, from a volume/value point of view, the significant area of unmet requirement and room for further development, combined with the large share of the pharmaceutical sector, make the GI therapeutics market an attractive target for therapeutic effect, where the development of new, affordable, and innovative, effective treatments could provide greater patients satisfaction, higher profit returns, and decreased economic burden.
In patients with GORD, one of the largest and fastest growing GI segments, the liquid content of the stomach regurgitates back up into the esophagus, causing ulcerations of the esophagus. The predominant symptom of which is the unpleasant sensation of heartburn, prominently at night. Acid suppressants used in the treatment of GORD include proton pump inhibitors, histamine H2 receptor antagonists, and antacids; however, proton pump inhibitors (PPI) have emerged as the most effective option for treatment.
Disease and illnesses of the gastrointestinal system have increased significantly in the last decade because of the considerable lifestyle changes. People with gastrointestinal illness have a high prevalence of depression, impaired central nervous system functioning, anxiety, and stress. The overall majority of self-reported gastrointestinal problems was 18%, with prominent variations among regions, and it increased with the rising age. Adults from the age group 45-54 and 55-64 years were prominently more prone to have gastrointestinal problems when compared to people below 44 years of age.
The China market dominated the Asia Pacific Gastrointestinal Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3, 846.3 million by 2028. The Japan market is experiencing a CAGR of 4.1% during (2022-2028). Additionally, The India market would display a CAGR of 5.3% during (2022-2028).
Based on Type, the market is segmented into Branded and Generics. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on Route of Administration, the market is segmented into Injectable and Oral & Others. Based on Application, the market is segmented into Crohn's Disease, Ulcerative Colitis, GERD, IBS and Others. Based on Drug Class, the market is segmented into Biologics/Biosimilar, Anti-Diarrheal, Anti-Emetics, Digestive Enzymes, Aminosalicylates, Proton Pump Inhibitors, Laxatives & H2 Antagonists and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, AbbVie, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.), Johnson & Johnson (Janssen Global Services, LLC), AstraZeneca PLC, Bayer AG, Sun Pharmaceutical Industries Ltd., and Cipla Limited.
Scope of the Study
By Type
- Branded
- Generics
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Route of Administration
- Injectable
- Oral & Others
By Application
- Crohn's Disease
- Ulcerative Colitis
- GERD
- IBS
- Others
By Drug Class
- Biologics/Biosimilar
- Anti-Diarrheal
- Anti-Emetics
- Digestive Enzymes
- Aminosalicylates
- Proton Pump Inhibitors
- Laxatives & H2 Antagonists
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Gastrointestinal Therapeutics Market, by Type
1.4.2 Asia Pacific Gastrointestinal Therapeutics Market, by Distribution Channel
1.4.3 Asia Pacific Gastrointestinal Therapeutics Market, by Route of Administration
1.4.4 Asia Pacific Gastrointestinal Therapeutics Market, by Application
1.4.5 Asia Pacific Gastrointestinal Therapeutics Market, by Drug Class
1.4.6 Asia Pacific Gastrointestinal Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Gastrointestinal Therapeutics Market
Chapter 4. Asia Pacific Gastrointestinal Therapeutics Market by Type
4.1 Asia Pacific Branded Market by Country
4.2 Asia Pacific Generics Market by Country
Chapter 5. Asia Pacific Gastrointestinal Therapeutics Market by Distribution Channel
5.1 Asia Pacific Retail Pharmacies Market by Country
5.2 Asia Pacific Hospital Pharmacies Market by Country
5.3 Asia Pacific Online Pharmacies Market by Country
Chapter 6. Asia Pacific Gastrointestinal Therapeutics Market by Route of Administration
6.1 Asia Pacific Injectable Market by Country
6.2 Asia Pacific Oral & Others Market by Country
Chapter 7. Asia Pacific Gastrointestinal Therapeutics Market by Application
7.1 Asia Pacific Crohn's Disease Market by Country
7.2 Asia Pacific Ulcerative Colitis Market by Country
7.3 Asia Pacific GERD Market by Country
7.4 Asia Pacific IBS Market by Country
7.5 Asia Pacific Others Market by Country
Chapter 8. Asia Pacific Gastrointestinal Therapeutics Market by Drug Class
8.1 Asia Pacific Biologics/Biosimilar Market by Country
8.2 Asia Pacific Anti-Diarrheal Market by Country
8.3 Asia Pacific Anti-Emetics Market by Country
8.4 Asia Pacific Digestive Enzymes Market by Country
8.5 Asia Pacific Aminosalicylates Market by Country
8.6 Asia Pacific Proton Pump Inhibitors Market by Country
8.7 Asia Pacific Laxatives & H2 Antagonists Market by Country
8.8 Asia Pacific Others Market by Country
Chapter 9. Asia Pacific Gastrointestinal Therapeutics Market by Country
9.1 China Gastrointestinal Therapeutics Market
9.1.1 China Gastrointestinal Therapeutics Market by Type
9.1.2 China Gastrointestinal Therapeutics Market by Distribution Channel
9.1.3 China Gastrointestinal Therapeutics Market by Route of Administration
9.1.4 China Gastrointestinal Therapeutics Market by Application
9.1.5 China Gastrointestinal Therapeutics Market by Drug Class
9.2 Japan Gastrointestinal Therapeutics Market
9.2.1 Japan Gastrointestinal Therapeutics Market by Type
9.2.2 Japan Gastrointestinal Therapeutics Market by Distribution Channel
9.2.3 Japan Gastrointestinal Therapeutics Market by Route of Administration
9.2.4 Japan Gastrointestinal Therapeutics Market by Application
9.2.5 Japan Gastrointestinal Therapeutics Market by Drug Class
9.3 India Gastrointestinal Therapeutics Market
9.3.1 India Gastrointestinal Therapeutics Market by Type
9.3.2 India Gastrointestinal Therapeutics Market by Distribution Channel
9.3.3 India Gastrointestinal Therapeutics Market by Route of Administration
9.3.4 India Gastrointestinal Therapeutics Market by Application
9.3.5 India Gastrointestinal Therapeutics Market by Drug Class
9.4 South Korea Gastrointestinal Therapeutics Market
9.4.1 South Korea Gastrointestinal Therapeutics Market by Type
9.4.2 South Korea Gastrointestinal Therapeutics Market by Distribution Channel
9.4.3 South Korea Gastrointestinal Therapeutics Market by Route of Administration
9.4.4 South Korea Gastrointestinal Therapeutics Market by Application
9.4.5 South Korea Gastrointestinal Therapeutics Market by Drug Class
9.5 Singapore Gastrointestinal Therapeutics Market
9.5.1 Singapore Gastrointestinal Therapeutics Market by Type
9.5.2 Singapore Gastrointestinal Therapeutics Market by Distribution Channel
9.5.3 Singapore Gastrointestinal Therapeutics Market by Route of Administration
9.5.4 Singapore Gastrointestinal Therapeutics Market by Application
9.5.5 Singapore Gastrointestinal Therapeutics Market by Drug Class
9.6 Malaysia Gastrointestinal Therapeutics Market
9.6.1 Malaysia Gastrointestinal Therapeutics Market by Type
9.6.2 Malaysia Gastrointestinal Therapeutics Market by Distribution Channel
9.6.3 Malaysia Gastrointestinal Therapeutics Market by Route of Administration
9.6.4 Malaysia Gastrointestinal Therapeutics Market by Application
9.6.5 Malaysia Gastrointestinal Therapeutics Market by Drug Class
9.7 Rest of Asia Pacific Gastrointestinal Therapeutics Market
9.7.1 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Type
9.7.2 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Distribution Channel
9.7.3 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Route of Administration
9.7.4 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Application
9.7.5 Rest of Asia Pacific Gastrointestinal Therapeutics Market by Drug Class
Chapter 10. Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 SWOT Analysis
10.2 AbbVie, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Approvals and Trials:
10.3 Takeda Pharmaceutical Company Limited
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Partnerships, Collaborations, and Agreements:
10.3.5.2 Acquisition and Mergers:
10.4 Pfizer, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Regional & Segmental Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.5 Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Product Launches and Product Expansions:
10.6 Johnson & Johnson (Janssen Global Services, LLC)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental &Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 AstraZeneca PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.8 Bayer AG
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental and Regional Analysis
10.8.4 Research & Development Expense
10.9 Sun Pharmaceutical Industries Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Research & Development Expenses
10.10. Cipla Limited
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expense
Companies Mentioned
- Abbott Laboratories
- AbbVie, Inc.
- Takeda Pharmaceutical Company Limited
- Pfizer, Inc.
- Salix Pharmaceuticals, Inc. (Bausch Health Companies, Inc.)
- Johnson & Johnson (Janssen Global Services, LLC)
- AstraZeneca PLC
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Cipla Limited
Methodology
LOADING...
